Who Paid My Doc
Andrew Friede
Addiction Medicine Portland, OR Medical Doctor
NPI 1063979060 CMS profile 6910703
111 Sw 5Th Ave, Portland, OR 97204
General payments
$1,141
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Andrew Friede of Portland, OR is reported in the CMS Open Payments database as having received $1,141 across 28 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 81st percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $35 | 2 | |
| 2021 | General | $150 | 2 | |
| 2020 | General | $68 | 3 | |
| 2019 | General | $888 | 21 |
Beside peers
- Andrew Friede
- Addiction Medicine median
- Middle half of Addiction Medicine
- National median
In program year 2025, general payments to Andrew Friede were reported at $0. Among 112 Addiction Medicine profiles paid that year, the median was $106 and the middle half received between $39 and $304.
Show as a table
| Year | Andrew Friede | Addiction Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $888 | $123 | $45–$285 | $163 |
| 2020 | $68 | $47 | $18–$148 | $114 |
| 2021 | $150 | $56 | $19–$158 | $132 |
| 2022 | $35 | $50 | $23–$177 | $149 |
| 2023 | $0 | $74 | $26–$159 | $160 |
| 2024 | $0 | $87 | $31–$187 | $164 |
| 2025 | $0 | $106 | $39–$304 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
121
Drug cost
$12,496
Branded share of claims
52.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Vraylar Cariprazine Hcl | Brand | 11 | $10,753 | |
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 13 | $1,131 | |
| Bupropion Xl Bupropion Hcl | Brand | 21 | $193 | |
| Prazosin Hcl | Generic | 15 | $162 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 18 | $85 | |
| Gabapentin | Generic | 12 | $75 | |
| Duloxetine Hcl | Generic | 11 | $65 | |
| Lamotrigine | Generic | 20 | $32 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 382 Part D prescribers listed as Addiction Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$28,295
Medicare patients
14
Services billed
354
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Depression | 75% | |
| COPD | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
28 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Medicine in Oregon
Related records
Addiction Medicine in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.